ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012
Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Pooled it
- A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).BMC medicine · 2016Trial
- Conocarpan and Eupomatenoid-6 as Natural Prototypes for Antituberculosis Compounds.International journal of microbiology · 2026Article
- Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026Review
- Pyridazine and pyridazinone compounds in crops protection: a review.Molecular diversity · 2025Review
- An Overview of Various Rifampicin Analogs againstMedicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- Article
- OvercomingActa pharmaceutica Sinica. B · 2022Review
- Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa.Antimicrobial agents and chemotherapy · 2020Article
- Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.Molecular genetics and metabolism · 2019Article
- Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.Tuberculosis (Edinburgh, Scotland) · 2018Review
- Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.Annals of clinical microbiology and antimicrobials · 2017Review
- Preclinical Efficacy Testing of New Drug Candidates.Microbiology spectrum · 2017Review
- Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.PLoS computational biology · 2017Article
- Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.Journal of pharmaceutical sciences · 2017Article
- Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.Antimicrobial agents and chemotherapy · 2016Article
- Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Review
- New Antituberculosis Drugs: From Clinical Trial to Programmatic Use.Infectious disease reports · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
Treatment of drug-resistant tuberculosis is hindered by the high toxicity and poor efficacy of second-line drugs. New compounds must be used together with existing drugs, yet clinical trials to optimize combinations of drugs for drug-resistant tuberculosis are lacking. We conducted an extensive review of existing in vitro, animal, and clinical studies involving World Health Organization-defined group 1, 2, and 4 drugs used in drug-resistant tuberculosis regimens to inform clinical trials and identify critical research questions. Results suggest that optimizing the dosing of pyrazinamide, the injectables, and isoniazid for drug-resistant tuberculosis is a high priority. Additional pharmacokinetic, pharmacodynamic, and toxicodynamic studies are needed for pyrazinamide and ethionamide. Clinical trials of the comparative efficacy and appropriate treatment duration of injectables are recommended. For isoniazid, rapid genotypic tests for Mycobacterium tuberculosis mutations should be nested in clinical trials. Further research focusing on optimization of dose and duration of drugs with activity against drug-resistant tuberculosis is paramount.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.